Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Clinical trial NCT04335136 · COMPLETED
Trial details
- NCT number
- NCT04335136
- Sponsor
- Apeiron Biologics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-30
- Primary completion
- 2020-12-26
- Enrollment
- 185
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.